Expert Interview
A Second Look: Discussing the top line results of Cellectar's CLOVER WaM of Iopofosine I-131 in Waldenstrom Macroglobulinemia
Ticker(s): CLRBInstitution: Mass General
- Clinical investigator and attending physician at Massachusetts General Hospital Cancer Center.
- Treats patients with plasma cell dyscrasias with a particular focus on multiple myeloma as well as Waldenstrom’s macroglobulinemia and other IgM-related disorders.
- Research interests include global health, studying immune dysregulation, and developing more effective oncologic treatment strategies, which minimize toxicity and infectious complications.
How do you feel about this study now both efficacy and toxicity?
Please describe what the typical failed 3rd line WM patient looks like under current standard of care, and compare to what you think Iopofosine131 would look like if given the drug.
Assuming Iopofosine 131 is approved do you think oncologist will move rapidly towards this new treatment paradigm?
Given the data set released on Jan 8th, and maybe making the assumption the data continues to improve, what do you think the likelihood is for Iopofosine 131 to eventually make it to 2nd/1st line?
Do you think the Cellectar should be moving rapidly towards any other indications, and if so which ones?
How would you compare Iopofosine storage/administration logistics with Azedra (iobenguane I-131) that’s being discontinued due to apparent administration logistics issue ?
how much larger is the 2nd line than 3rd line? what does that do to the total US population of potential candidates ?
what do you think of 131 for gliomas' in light of yesterday news on cns clearance ?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
